Endocrinology

An analysis of data from type 1 diabetes prevention trials is shedding new light on factors associated with increased and decreased likelihood of screening for type 1 diabetes among participants considered eligible for each trial.

Eight studies provided evidence to suggest the relationship between diabetes and the onset of frozen shoulder, but more high-quality cohort studies may be necessary to better understand the nature of the relationship.

A systematic review and meta-analysis of observational studies of people with diabetes suggest more than 1-in-4 also had a diagnosis of osteoporosis.

MAFLD-lean and MAFLD-diabetes subgroups recorded a higher risk of all-cause and disease-specific mortality compared to the MAFLD-overweight/obese group.

A patient in their mid-50s with a history of diabetes who had already been on antibiotics for 4 days for cellulitis diagnosed in your emergency department, but had not improved, and then, yesterday, noticed an ankle wound. What additional testing should be considered for this patient?

To celebrate the end of 2022 and the advances witnessed in the past year, our editorial team has created a list of the top 8 most popular pieces of content related to endocrinology from 2022.

Our editorial team is celebrating the end of 2022 by recapping our most popular content related to diabetes technology from the past year.

Our editorial team is kicking off the final week of the year by recapping our the most talked about approvals and clearances related to diabetes management from the US Food and Drug Administration in 2022, including tirzepatide, teplizumab, Dexcom G7, and more!

The last full weekend of each month, our editorial team compiles a list of our most popular endocrinology content from the past month for a month in review recap. The December 2022 endocrinology month in review features coverage of the FDA’s clearance of Dexcom G7, new data related to use of SGLT2 inhibitors in pediatric type 2 diabetes, and the ADA's Standards of Care in Diabetes—2023.

A systematic review and meta-analysis of studies reporting the pooled prevalence of obesity in pediatric type 2 diabetes suggest 75% of these patients had obesity.

Reflections on a century's worth of developments toward a major breakthrough in T1D this year.

Beginning January 1, 2023, all new content and insights from the editorial teams of Endocrinology Network, Practical Cardiology and Rheumatology Network will be hosted on HCPLive.Com.

On December 8, Dexcom announced their Dexcom G7 CGM system had received US FDA clearance for use in people with all types of diabetes aged 2 years and older.

The Endocrine Society has released updated guidance for management of hypoglycemia in people with diabetes, which represents their first guidance on the topic since 2009 and places a new emphasis on the role of diabetes technology, insulin analogs, and glucagon use.

Data from the BAPO trial suggests use of oral butyrate supplementation was associated with a 40% absolute increase in rate of the trial's BMI-based primary outcome at 6 months relative to placebo therapy in a population of pediatric patients with obesity.

Our latest endocrine case report features a woman in her 40s with a history of diabetes mellitus presenting with flu-like illness with multiple symptoms. Can you determine the correct diagnosis?

Gregory Weiss, MD, provides perspective on how improved safety of these procedures has revolutionized the way clinicians view use of bariatric and metabolic surgeries as a method for inducing weight loss in people with overweight and obesity.

An analysis of survey data from more than 1400 adults in the UK provides insight into potential risk factors for developing long COVID symptoms, with results indicating both female sex and increased body mass index as potential risk factors.

Results of the DIRECT-PLUS trial provide clinicians with new insights into the impact of the Mediterranean diet and a modified Mediterranean diet as a method for inducing weight loss.

The November 2022 endocrine month in review features coverage of the FDA’s approval of teplizumab, new data related to use of GLP-1 receptor agonists, and a trio of stories on topics pertaining to diabetes technology.

A Johns Hopkins-led analysis provides a snapshot of trends in racial disparities seen in both uptake of and engagement in discussions with providers around continuous glucose monitoring and insulin pumps among adults with type 1 diabetes.

A single-arm study provides insight into the feasibility and acceptability of flash glucose monitoring use for promoting positive lifestyle changes among people with prediabetes.

Announced on November 17, the US FDA Class I recall for the Insulet Omnipod DASH Insulin Management System Personal Diabetes Manager comes after the company had received more than 450 complaints related to battery swelling, fluid leakage from battery, and extreme overheating, including 3 instances that included fires.

Insulin glargline-aglr is the second approved interchangeable biosimilar insulin product to insulin glargine indicated to improve glycemic control in patients with diabetes mellitus.

A 15-person study comparing flash monitoring to standard self-monitoring in people on hemodialysis with or without diabetes provides clinicians and researchers with insight into the potential clinical applicability of these devices in similar patient populations.

In this episode, our hosts are joined by Lydia Alexander, MD, president-elect of the Obesity Medicine Association, to discuss the updates in the landscape of obesity management as well as a deep dive into the recent American Gastroenterological Association guidelines for pharmacological management and the OMA's annual meeting.

Our latest endocrine case report from Brady Pregerson, MD, features a female in her 60s with a history of diabetes mellitus who presents to the ED for 3 days of inner right thigh pain. Can you determine the correct diagnosis?

A formal task analysis conducted in older adults with type 2 diabetes provides insight into the ease of use and task burden associated with uptake of the Dexcom G7 CGM system, with results indicating use of the system required fewer than half as many steps to initiate as previous generations of the CGM system.

At AHA 2022, Diana Isaacs, PharmD, provides perspective on the potential impact of optimized uptake of newer obesity medications could have on population-level cardiovascular disease prevention.